| Literature DB >> 35345075 |
Sanjukta Naik1, Suchanda Sahu1, Debapriya Bandyopadhyay1, Sujit Tripathy2.
Abstract
Background & objectives: Osteoarthritis (OA) is the 11th leading cause of disability in the modern world, but till date, there have been no effective markers for monitoring the progression of OA. The three proteins RANK/RANK-Ligand and Osteoprotegerin (OPG) have been found to be the key regulators of bone metabolism. Interaction of RANK-Ligand with its receptor RANK triggers differentiation of osteoclasts leading to bone resorption. OPG on the other hand is protective as it is expressed by osteoblasts and bind RANKL with higher affinity preventing its interaction with RANK. The levels of these serum proteins are regulated by vitamin D and parathyroid hormones. Therefore, the present study, aimed to study the association of serum RANKL, OPG and vitamin D with disease severity in patients with knee OA.Entities:
Keywords: Knee; RANK-L; osteoarthritis; osteoprotegerin; vitamin D
Mesh:
Substances:
Year: 2021 PMID: 35345075 PMCID: PMC9131798 DOI: 10.4103/ijmr.IJMR_873_19
Source DB: PubMed Journal: Indian J Med Res ISSN: 0971-5916 Impact factor: 5.274
Biochemical parameters in the two groups
| Parameters | Early stage | Late stage |
|---|---|---|
| ESR (mm/h) | 20.0±12.4 | 21.3±14.9 |
| CRP (mg/L) | 1.7±3.7 | 1.9±3.7 |
| Calcium (mg/dl) | 9.07±0.63 | 9.17±0.61 |
| Phosphates (mg/dl) | 1.8±3.05 | 1.1±1.7 |
| ALP (U/L) | 115.1±32 | 129.5±35 |
| Vitamin D (ng/ml) | 42.8±21.8 | 14.6±8.2*** |
| RANKL (ng/ml) | 1.08±1 | 3.5±2.6*** |
| OPG (ng/ml) | 750.28±261.8 | 616.2±299 |
P***<0.001. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALP, alanine aminotransferase; OPG, osteprotegerin; RANKL, receptor activator of nuclear kappa-B ligand
Correlation of disease severity with serum parameters
| Serum parameters | r |
|---|---|
| ESR | 0.080 |
| CRP | 0.020 |
| Calcium | −0.015 |
| Phosphate | −0.113 |
| ALP | 0.273 |
| Vitamin D | −0.708*** |
| RANKL | 0.575*** |
| OPG | −0.206 |
| RANKL/OPG ratio | 0.272* |
| VAS | 0.512*** |
P *< 0.05, ***<0.001. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALP, alanine aminotransferase; OPG, osteprotegerin; RANKL, receptor activator of nuclear kappa-B ligand; VAS, visual analogue score
Comparison of vitamin D, receptor activator of nuclear kappa-B ligand and receptor activator of nuclear kappa-B ligand/osteprotegerin according to severity of osteoarthritis
| Parameters | Mean±SD | |||
|---|---|---|---|---|
|
| ||||
| Grade 1 (n=19) | Grade 2 (n=22) | Grade 3 (n=22) | Grade 4 (n=17) | |
| Vitamin D** | 51.48±25.5 | 35.3±14.3 | 18.7±7.59 | 10.21±7.11 |
| RANKL*** | 0.76±0.81 | 1.36±1.31 | 2.68±2.2 | 4.52±2.89 |
| RANKL/OPG* | 0.01±0.038 | 0.002±0.005 | 0.14±0.6 | 0.61±1.43 |
One-way ANOVA P*< 0.05, **<0.01, ***<0.001. RANKL, receptor activator of nuclear kappa-B ligand; SD, standard deviation; OPG, osteprotegerin
Post hoc analysis of the ANOVA
| Grade 1 | Grade 2 | Grade 3 | ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Grade 2 | Grade 3 | Grade 4 | Grade 3 | Grade 4 | Grade 4 | |
| Vitamin D | 16.18 (3.1-29.2)** | 32.78 (19.7-45.8)*** | 41.27 (27.3-55.2)*** | 16.60 (4.0--29.1)** | 25.09 (11.6-38.5)*** | 8.49 (−4.9-21.9) |
| RANKL | -0.60 (−2.2-1.0) | -1.92 (−3.5-−0.28)* | -3.76 (−5.5-−2.0)*** | -1.31 (−2.8-0.26) | -3.15 (−4.8-−1.46)*** | -1.83 (−3.5-−0.14)* |
Values mentioned are mean difference (95% CI). P *< 0.05, **<0.01, ***<0.001. RANKL, receptor activator of nuclear kappa-B ligand; CI, confidence interval